105211-23-2Relevant academic research and scientific papers
Use of src SH2 specific compounds to treat a bone resorption disease
-
, (2008/06/13)
Invented is a method of treating a bone resorption disease in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human src SH2 domain with a binding affinity greater than fifty-fold higher than the binding affinity with which the compound binds to a human lck SH2 domain and a human fyn SH2 domain, and, binds to a human hcp SH2 domain, a human Grb2 SH2 domain, a human SH-PTP2 SH2 domain and a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such src SH2 domain.
Synthesis of Thyroid Hormone Analogues. Part 2. Oxidative Coupling Approach to SK&F L-94901
Hickey, Deirdre M. B.,Leeson, Paul D.,Carter, Steven D.,Goodyear, Michael D.,Jones, Sarah J.,et al.
, p. 3097 - 3102 (2007/10/02)
Asynthesis of L-3,5-dibromo-3'-thyronine-SK&F L-94901 (1), a novel, selective and potent thyromimetic-is described.The key step in this synthesis involves the formation of a hindered diaryl ether moiety.This paper
Synthesis of Thyroid Hormone Analogues. Part 3. Iodonium Salt Approaches to SK&F L-94901
Hickey, Deirdre M. B.,Leeson, Paul D.,Novelli, Riccardo,Shah, Virendra P.,Burpitt, Brian E.,et al.
, p. 3103 - 3112 (2007/10/02)
The key step in the synthesis of L-3,5-dibromo-3'--thyronine, SK&F L-94901 (1), a novel, selective, and potent thyromimetic, is the formation of the hindered diaryl ether moiety.This paper describes an investigation into the formation of the required diaryl ether by copper-catalysed reaction both of symmetrical iodonium salts (2a) and (10) and mixed iodonium salts (2b-e) with protected dibromotyrosine (5).The importance of the counter-ion of the iodonium salt is discussed.This work is extended to a large-scale synthesis of SK&F L-94901 (1).
Pyridyl and pyridazinyl substituted thyronine compounds having selective thyromimetic activity
-
, (2008/06/13)
This invention relates to chemical compounds which have selective thyromimetic activity. A compound of this invention is 3,5-dibromo-3''-[6-oxo-3(1H)-pyridazinylmethyl]-thyronine.
